N/A N=16 Comparison of a Septal Stapler to Suture Closure in Nasal Septoplasty
Nasal Obstruction
Primary: Operative Time — 35; 423 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=452 Integrating Contextual Factors Into Clinical Decision Support
Medical Errors · Decision Support Systems, Clinical · Diagnostic Errors
Primary: Resolution of Contextual Red Flags — 116; 240; 83; 99 Red flags — p=.91
Phase 2 N=12 [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET — 0 Participants
Phase 2 N=26 Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease
Chronic Kidney Disease · Sarcopenia · Frailty
Primary: Maximal Aerobic Capacity- CoQ10 — 21.4; 20.7; 20.7 mL/min/kg — p=0.33
Phase 2 N=140 Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Metastatic Melanoma · Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Recurrent Hodgkin Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab — 0; 0; 5; 0 Participants
Phase 3 N=631 Efficacy, Tolerability, and Safety of DFN-15
Migraine Headache
Primary: Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (First Treated Double-blind Treatment Period) — 25.8; 32.9; 24.6; 32.4 percentage of subjects — p=0.075
Phase 1 N=36 Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
Advanced Malignant Solid Neoplasm · HIV Infection · Metastatic Malignant Solid Neoplasm
Primary: Incidence of Adverse Events — 6; 7; 7; 6 Participants
Phase 2 N=36 Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC
Advanced Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) Within the First Cycle — 1 Participants
N/A N=74 Comparison of a Daily Disposable Multifocal Contact Lens to a Marketed Product
Visual Acuity
Primary: Binocular logMAR Visual Acuity — -0.076; -0.081; 0.006; -0.013 LogMAR
N/A N=21 Duration of Antibiotic Treatment for Early VAP (DATE) Trial
Early Ventilator Associated Pneumonia
Primary: Clinical Response — 2.9; 2.9 score on a scale — p=<0.01
Phase 2 N=25 Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm
Parkinson Disease
Primary: Change in Quantitative Biomechanics 1 (Clinical Motor Ratings MDS-UPDRS) — 38; 34; 28; 36.75 units on a scale — p=0.391
N/A N=201 Study of Nutrition and Activity in Kids
Obesity, Adolescent · Adolescent Behavior
Primary: zBMI Change — 0.433; 0.55; 0.376; 0.61 z-score
N/A N=180 Xpede Clinical Study
Pathological Fracture of Vertebra Due to Secondary Osteoporosis (Disorder) · Pathological Fracture of Vertebra Due to Neoplastic Disease (Disorder)
Primary: The Change of Numerical Rating Scale (NRS) Score From Baseline at 6 Months Postoperative — -4.2; -4.4 score
Phase 2 N=154 A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15. — 2.020; 2.398; 2.515 units on a scale
Phase 1 N=8 Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed